GTBPGT Biopharma, Inc.
The schedule
- Thu15Oct
GTBP faces Nasdaq minimum bid price compliance issues. A reverse split may be required to maintain listing, a move that typically pressures retail sentiment.
- Tue10Nov
Presentation of early clinical or preclinical data from the TriKE NK-cell engager platform, likely focusing on GTB-5550 in solid tumors.
- Thu11Feb
Q3 results will detail the financial impact of fall clinical activities and update the market on any post-conference strategic developments.
- Wed12May
Full-year 2026 financial and operating results, setting guidance for 2027 pipeline milestones.
- Fri14May
First quarter 2027 earnings, with a focus on Phase 1 expansion data timelines and potential new IND filings.
Past
- Thu13Aug
The Q2 print will update investors on cash runway, R&D expenses, and clinical progression of GTB-5550 following its recent Phase 1 dosing.
- Wed5Aug
With a market cap near $3.1M and high cash burn, GTBP faces imminent need to secure capital. The base case is a highly dilutive equity offering or ATM utilization, which would dramatically increase the share count.
- Sat20Jun
Actual outcome: Bear · $0.35 at outcome
GT Biopharma's mid-year update on its TriKE NK-cell engager platform failed to deliver the definitive clinical progress or IND advancement investors were anticipating. The lack of near-term clinical validation or breakthrough preclinical data disappointed the market, leading to a 10.3% decline in the stock.
Around the mid-year oncology conference window, GT Biopharma is likely to provide a substantive update on its TriKE NK-cell engager platform—whether that is new preclinical data, IND progress, or early clinical design—creating a binary setup for the stock.
- Fri15May
Actual outcome: Bull · $0.45 at outcome
GT Biopharma announced the dosing of the first patient in its Phase 1 trial for GTB-5550, expanding its TriKE platform into solid tumors. This key clinical milestone, combined with ongoing progress for GTB-3650 and positive industry sentiment surrounding B7-H3 targets, overshadowed cash burn concerns and drove the stock's double-digit rally.
Q1 2026 10-Q should update GT Biopharma’s cash runway and R&D spend on its TriKE immuno-oncology programs; with no revenue, the market will focus on burn rate versus the roughly $6.8M cash balance and any color on upcoming clinical milestones.
